DXCM (DexCom) Total Equity: $2,957 Mil (As of Mar. 2026)


DXCM DexCom Inc DXCM
90 GF Score
Price $69.75
GF Value $103.54
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is DexCom Total Equity?

DexCom DXCM +1.18% 90 Total Equity is $2,957 Mil as of Mar. 2026. GuruFocus rates DXCM with a GF Score™ of 90/100 and a GF Value™ of $103.54 (Significantly Undervalued). The stock has 3 warning signs investors should review.

DexCom's total equity for the quarter that ended in Mar. 2026 was $2,957 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

DexCom Total Equity Historical Data

* Premium members only.

The historical data trend for DexCom's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Total Equity Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,042.10 2,131.80 2,068.60 2,102.60 2,746.00

DexCom Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,266.60 2,573.10 2,726.10 2,746.00 2,956.90
DXCM
90GF Score
DexCom Inc DXCM
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

DexCom's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=6339.9-3593.9
=2,746

DexCom's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=6633.3-3676.4
=2,957

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $2,957 Mil mean?
DexCom (DXCM) has a Total Equity of $2,957 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for DexCom and its competitors.
Is DexCom's Total Equity too high?
DexCom's current Total Equity is $2,957 Mil. Overall, DexCom has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's Total Equity compare to GEHC and STE?
DexCom's Total Equity of $2,957 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for DexCom and its competitors. DexCom's current Total Equity is $2,957 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Significantly Undervalued. The stock's GF Value™ is $103.54, compared to a current price of $69.75 — trading 32.6% below its estimated fair value. The current Total Equity is $2,957 Mil. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For DexCom (DXCM), the current Total Equity is $2,957 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of $69.75 is trading 32.6% below its estimated GF Value™ of $103.54. GuruFocus considers DexCom to be Significantly Undervalued.

Key valuation signals for DXCM:

  • Total Equity: $2,957 Mil
  • GF Value™: $103.54 vs. price of $69.75 (32.6% below fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score

Get the complete analysis for DXCM

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$69.75
Price
$103.54
GF Value